CD274 and non-small cell lung carcinoma: Indeed, primary analysis of the CITYSCAPE trial examining combined anti-TIGIT antibody tiragolumab plus anti-PD-L1 atezolizumab for locally advanced or metastatic NSCLC suggested a significant improvement in overall response rate and progression-free survival (132).